TrialFuture oncology (London, England)2026

Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma.

Nathalie A Johnson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.